Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has issued a complete response letter (CRL) for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-small cell lung cancer (NSCLC), saying the drug failed to show a statistically significant overall survival benefit. While the Phase 3 HARMONi trial showed improved progression-free survival, the FDA determined that wasn't enough to support approval. Summit Therapeutics says it remains committed to advancing ivonescimab's development.
The FDA has declined to approve ivonescimab — a PD-1/VEGF bispecific antibody — combined with platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC whose disease progressed after EGFR TKI therapy. The agency issued a complete response letter (CRL), concluding that a progression-free survival (PFS) benefit alone, without a statistically significant overall survival (OS) improvement, does not support a favorable benefit-risk profile.
The decision was based on data from the global Phase 3 HARMONi trial, which enrolled 438 patients. While the trial met its PFS endpoint, the OS difference fell just short of statistical significance. Summit Therapeutics expressed disappointment but reaffirmed its commitment to ivonescimab's broader clinical development program.
By the Numbers:
Why it matters: This CRL reinforces the FDA's position that PFS improvements alone are insufficient for approval in this setting — a critical signal for oncology drug developers. Patients with EGFR-mutated NSCLC post-TKI progression continue to face limited treatment options.